Suzhou Ribo Life Science Co., Ltd. (HKG:6938)

Market Cap	8.71B
Revenue (ttm)	165.26M +4.1%
Net Income	-309.43M
EPS	-2.35
Shares Out	170.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	416,000
Open	52.00
Previous Close	50.00
Day's Range	48.60 - 52.45
52-Week Range	43.60 - 95.80
Beta	n/a
Analysts	Strong Buy
Price Target	102.57 (+100.92%)
Earnings Date	Jun 26, 2026

About Suzhou Ribo Life Science

Suzhou Ribo Life Science Co., Ltd. researches and develops novel therapeutics for the treatment of cardiovascular, metabolic, renal, and liver diseases in Chinese mainland and internationally. It develops RBD4059, which is phase 2 clinical trial for treating thrombotic diseases; RBD5044 that is in phase 2 clinical trial for treating hypertrigly ceridemia; RBD7022, which is in phase 2 clinical trial for the treatment of hypercho lesterolemia; RBD7007 and RBD2080 that are in Phase I clinical trial for the treatment of renal diseases; and RBD1119 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 407
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6938

Financial Performance

In 2025, Suzhou Ribo Life Science's revenue was 148.51 million, an increase of 4.12% compared to the previous year's 142.63 million. Losses were -278.06 million, 2.93% more than in 2024.

Financial numbers in CNY

Analyst Summary

According to 5 analysts, the average rating for 6938 stock is "Strong Buy." The 12-month stock price target is $102.57, which is an increase of 100.92% from the latest price.

Price Target

$102.57

(100.92% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error